Login to Your Account



Amgen Gaining Rights to CCR4 Antibody in $520M Kyowa Deal

By Jennifer Boggs


Friday, March 7, 2008
Amgen Inc. is expanding its early clinical pipeline with the addition of a CCR4 antibody licensed from Kyowa Hakko Kogyo Co. Ltd. in exchange for $100 million up front and up to $420 million in milestones. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription